Statin therapy: time for a precision medicine approach?

References

• Anderson TJ, Gregoire J, Pearson GJ, et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282.
   PubMed Web of Science ®Google Scholar
• Gryn SE, Hegele RA. Pharmacogenomics, lipid disorders, and treatment options. Clin Pharmacol Ther. 2014;96(1):36–47.
   PubMed Web of Science ®Google Scholar
• Arrigoni E, Del Re M, Fidilio L, et al. Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins. Int J Mol Sci. 2017;18(1):104.
   PubMed Web of Science ®Google Scholar
• Leusink M, Onland-Moret NC, de Bakker PI, et al. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17(2):163–180.
   PubMed Web of Science ®Google Scholar
• Alfonsi JE, Hegele RA, Gryn SE. Pharmacogenetics of lipid-lowering agents: precision or indecision medicine? Curr Atheroscler Rep. 2016;18(5):24.
   PubMed Web of Science ®Google Scholar
• Natarajan P, Young R, Stitziel NO, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017;135(22):2091–2101.
   PubMed Web of Science ®Google Scholar
• Leusink M, Maitland-van der Zee AH, Ding B, et al. A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics. 2016;17(6):583–591.
   PubMed Web of Science ®Google Scholar
• Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385(9984):2264–2271.
   PubMed Web of Science ®Google Scholar
• Gelissen IC, McLachlan AJ. The pharmacogenomics of statins. Pharmacological Res. 2014;88:99–106.
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001;276(38):35669–35675.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5(6):352–358.
   PubMed Web of Science ®Google Scholar
• Hopewell JC, Parish S, Offer A, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the heart protection study. Eur Heart J. 2013;34(13):982–992.
   PubMed Web of Science ®Google Scholar
• Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5(2):257–264.
   PubMed Web of Science ®Google Scholar
• Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068.
   PubMed Web of Science ®Google Scholar
• Akao H, Polisecki E, Kajinami K, et al. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis. 2012;220(2):413–417.
   PubMed Web of Science ®Google Scholar
• Couvert P, Giral P, Dejager S, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics. 2008;9(9):1217–1227.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Lee VW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010;87(5):558–562.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197–203.
   PubMed Web of Science ®Google Scholar
• Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291(23):2821–2827.
   PubMed Web of Science ®Google Scholar
• Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008;117(12):1537–1544.
   PubMed Web of Science ®Google Scholar
• Shiffman D, Trompet S, Louie JZ, et al. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PloS One. 2012;7(5):e38240.
   PubMed Web of Science ®Google Scholar
• Polisecki E, Muallem H, Maeda N, et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008;200(1):109–114.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hyde CL, Wood LS, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet. 2009;2(2):173–181.
   PubMed Web of Science ®Google Scholar
• Mega JL, Morrow DA, Brown A, et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009;29(9):1310–1315.
   PubMed Web of Science ®Google Scholar
• Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res. 2012;53(5):1000–1011.
   PubMed Web of Science ®Google Scholar
• Barber MJ, Mangravite LM, Hyde CL, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PloS One. 2010;5(3):e9763.
   PubMed Web of Science ®Google Scholar
• Dube JB, Boffa MB, Hegele RA, et al. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23(2):133–140.
   PubMed Web of Science ®Google Scholar
• Smit RA, Postmus I, Trompet S, et al. Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment. Pharmacogenomics. 2016;17(15):1621–1628.
   PubMed Web of Science ®Google Scholar
• Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41(1):47–55.
   PubMed Web of Science ®Google Scholar
• Bos D, Ikram MA, Isaacs A, et al. Genetic loci for coronary calcification and serum lipids relate to aortic and carotid calcification. Circ Cardiovasc Genet. 2013;6(1):47–53.
   PubMed Web of Science ®Google Scholar
• Isaacs A, Willems SM, Bos D, et al. Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(9):2233–2239.
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016;48(6):634–639.
   PubMed Web of Science ®Google Scholar
• Joseph PG, Pare G, Asma S, et al. Impact of a genetic risk score on myocardial infarction risk across different ethnic populations. Can J Cardiol. 2016;32(12):1440–1446.
   PubMed Web of Science ®Google Scholar
• Morris RW, Cooper JA, Shah T, et al. Marginal role for 53 common genetic variants in cardiovascular disease prediction. Heart. 2016;102(20):1640–1647.
   PubMed Web of Science ®Google Scholar
• Hindieh W, Pilote L, Cheema A, et al. Association between family history, a genetic risk score, and severity of coronary artery disease in patients with premature acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2016;36(6):1286–1292.
   PubMed Web of Science ®Google Scholar
• Natarajan P, Young R, Stitziel NO, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017.
   Web of Science ®Google Scholar
• Kullo IJ, Jouni H, Austin EE, et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the MI-GENES clinical trial). Circulation. 2016;133(12):1181–1188.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400–408.
   PubMed Web of Science ®Google Scholar